NO964008L - Substituerte azetidinonforbindelser som er anvendbare som hypokolesterolemiske midler - Google Patents

Substituerte azetidinonforbindelser som er anvendbare som hypokolesterolemiske midler

Info

Publication number
NO964008L
NO964008L NO964008A NO964008A NO964008L NO 964008 L NO964008 L NO 964008L NO 964008 A NO964008 A NO 964008A NO 964008 A NO964008 A NO 964008A NO 964008 L NO964008 L NO 964008L
Authority
NO
Norway
Prior art keywords
aryl
lower alkyl
substituted
halogen
hydrogen
Prior art date
Application number
NO964008A
Other languages
English (en)
Norwegian (no)
Other versions
NO964008D0 (no
Inventor
Michael P Kirkup
Sundeep Dugar
Bandarpalle B Shankar
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO964008D0 publication Critical patent/NO964008D0/no
Publication of NO964008L publication Critical patent/NO964008L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30—Preparation of optical isomers
    • C07C227/32—Preparation of optical isomers by stereospecific synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO964008A 1994-03-25 1996-09-24 Substituerte azetidinonforbindelser som er anvendbare som hypokolesterolemiske midler NO964008L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21849894A 1994-03-25 1994-03-25
PCT/US1995/003196 WO1995026334A1 (fr) 1994-03-25 1995-03-22 Composes d'azetidinone substituee utiles comme agents hypocholesterolemiques

Publications (2)

Publication Number Publication Date
NO964008D0 NO964008D0 (no) 1996-09-24
NO964008L true NO964008L (no) 1996-11-22

Family

ID=22815366

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964008A NO964008L (no) 1994-03-25 1996-09-24 Substituerte azetidinonforbindelser som er anvendbare som hypokolesterolemiske midler

Country Status (20)

Country Link
US (2) US5627176A (fr)
EP (1) EP0751934B1 (fr)
JP (1) JP3524927B2 (fr)
KR (1) KR100338171B1 (fr)
CN (1) CN1144522A (fr)
AT (1) ATE183738T1 (fr)
AU (1) AU686361B2 (fr)
CA (1) CA2186364C (fr)
CZ (1) CZ281596A3 (fr)
DE (1) DE69511687T2 (fr)
DK (1) DK0751934T3 (fr)
ES (1) ES2135050T3 (fr)
FI (1) FI963817A7 (fr)
GR (1) GR3031105T3 (fr)
HU (1) HU221309B1 (fr)
NO (1) NO964008L (fr)
NZ (1) NZ283528A (fr)
PL (1) PL316431A1 (fr)
SK (1) SK119796A3 (fr)
WO (1) WO1995026334A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
PT877750E (pt) 1995-10-31 2002-09-30 Schering Corp 2-azetidinonas substituidas por acucar uteis como agentes hipocolesterolemiantes
AU7472896A (en) * 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AU4343500A (en) 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
ATE279425T1 (de) * 2000-12-20 2004-10-15 Schering Corp Zuckersubstituierte 2-azetidinone verwendbar als hypocholesterdenische arzneimittel
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
KR20070120617A (ko) * 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
NZ542090A (en) * 2001-01-26 2006-09-29 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1911462A3 (fr) 2001-01-26 2011-11-30 Schering Corporation Combinaisons comprenant un inhibiteur d'absorption de stérol
BRPI0208384B1 (pt) 2001-03-28 2016-05-31 Merck Sharp & Dohme síntese enantiosseletiva de compostos intermediários de azetidinona
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1859796A3 (fr) * 2001-09-21 2008-07-02 Schering Corporation Treatment de xanthoma avec des dérivés d'azétidines en tant qu'inhibiteurs d'absorption des stérols
EP1429756B1 (fr) * 2001-09-21 2006-11-22 Schering Corporation Methodes et combinaisons therapeutiques utiles pour le traitement du xanthome effectue avec des inhibiteurs d'absorption du sterol
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
CA2504916A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
WO2004081004A1 (fr) 2003-03-07 2004-09-23 Schering Corporation Composes d'azetidinone substitues, formulations et utilisations de ceux-ci pour traiter l'hypercholesterolemie
DE602004018617D1 (de) * 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081002A1 (fr) 2003-03-07 2004-09-23 Schering Corporation Composes d'azetidinone substitues, leurs formulations et utilisations en vue du traitement de l'hypercholesterolemie
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1918000A2 (fr) 2003-11-05 2008-05-07 Schering Corporation Combinaisons d'agents de modulation lipide et azétidinones substitués et traitements pour conditions vasculaires
WO2005046797A2 (fr) * 2003-11-05 2005-05-26 Schering Corporation Combinaisons de modulateurs lipidiques et d'azetidinones substituees et traitements d'affections vasculaires
JP2007516287A (ja) * 2003-12-23 2007-06-21 メルク　エンド　カムパニー　インコーポレーテッド 抗高コレステロール血症化合物
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
JP4590417B2 (ja) * 2004-01-16 2010-12-01 メルク・シャープ・エンド・ドーム・コーポレイション Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法
EP1807070A1 (fr) * 2004-09-29 2007-07-18 Schering Corporation Combinaisons d'azetidinones substituees et d'antagonistes cb1
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
DE602006010870D1 (de) * 2005-06-20 2010-01-14 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
WO2007084450A2 (fr) 2006-01-18 2007-07-26 Schering Corporation Modulateurs de recepteurs de cannibinoides
US7910698B2 (en) * 2006-02-24 2011-03-22 Schering Corporation NPC1L1 orthologues
WO2007103453A1 (fr) * 2006-03-06 2007-09-13 Teva Pharmaceutical Industries Ltd. Compositions à base d'ézétimibe
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
WO2008108486A1 (fr) 2007-03-06 2008-09-12 Teijin Pharma Limited Dérivés de 1-biarylazétidinone
WO2008130616A2 (fr) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines comme modulateurs des récepteurs cb1
JP2010529148A (ja) * 2007-06-07 2010-08-26 テバ ファーマシューティカル インダストリーズ リミティド エゼチミブ製造のための還元方法
WO2009005646A2 (fr) * 2007-06-28 2009-01-08 Schering Corporation Pipérazines à substitution servant d'antagonistes des récepteurs cb1
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
US20090093627A1 (en) * 2007-08-30 2009-04-09 Lorand Szabo Process for preparing intermediates of ezetimibe by microbial reduction
CN101200443B (zh) * 2007-10-17 2011-06-29 中国药科大学 氮杂环丁酮衍生物、其制备方法及含有它们的药物组合
WO2010100255A1 (fr) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Compositions pharmaceutiques hypocholestérolémiques
CN101993403B (zh) * 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
HUE052300T2 (hu) 2012-05-01 2021-04-28 Althera Life Sciences Llc Orális tablettakészítmény, amely a rozuvastatin és az ezetimib rögzített kombinációjából áll, hiperlipidémia és kardiovaszkuláris betegségek kezelésére
JP5969958B2 (ja) * 2013-06-27 2016-08-17 国立大学法人お茶の水女子大学 光学活性含フッ素アミノ酸類の製造方法
CN105294426B (zh) * 2014-06-09 2019-05-14 浙江海正药业股份有限公司 氮杂环丁酮化合物制备方法及其中间体
CN104860980B (zh) * 2015-04-23 2018-06-19 上海弈柯莱生物医药科技有限公司 一种用于合成依折麦布的中间体及其制备方法和应用
BR112019015107A2 (pt) 2017-01-23 2020-03-10 Dong Wha Pharm. Co., Ltd. Formulação de complexo compreendendo inibidor de hmg-coa redutase e clopidogrel

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
JPH02268144A (ja) * 1989-04-11 1990-11-01 Ube Ind Ltd β―アミノエステルの製造法
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
AU658441B2 (en) * 1991-07-23 1995-04-13 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof

Also Published As

Publication number Publication date
WO1995026334A1 (fr) 1995-10-05
SK119796A3 (en) 1997-05-07
PL316431A1 (en) 1997-01-06
DK0751934T3 (da) 1999-12-13
CA2186364A1 (fr) 1995-10-05
EP0751934A1 (fr) 1997-01-08
ATE183738T1 (de) 1999-09-15
HU221309B1 (en) 2002-09-28
JPH09510970A (ja) 1997-11-04
CZ281596A3 (en) 1997-05-14
NO964008D0 (no) 1996-09-24
US5627176A (en) 1997-05-06
FI963817A0 (fi) 1996-09-25
JP3524927B2 (ja) 2004-05-10
ES2135050T3 (es) 1999-10-16
GR3031105T3 (en) 1999-12-31
EP0751934B1 (fr) 1999-08-25
DE69511687T2 (de) 2000-03-16
FI963817A7 (fi) 1996-09-25
MX9604030A (es) 1997-09-30
CN1144522A (zh) 1997-03-05
DE69511687D1 (de) 1999-09-30
KR100338171B1 (ko) 2002-11-23
HUT74887A (en) 1997-02-28
KR970702246A (ko) 1997-05-13
HU9602616D0 (en) 1996-11-28
AU686361B2 (en) 1998-02-05
NZ283528A (en) 1997-12-19
US5688990A (en) 1997-11-18
CA2186364C (fr) 2008-12-30
AU2159695A (en) 1995-10-17

Similar Documents

Publication Publication Date Title
CA2186364A1 (fr) Composes d'azetidinone substituee utiles comme agents hypocholesterolemiques
US4997854A (en) Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
CA2426430C (fr) Composes biaryle utilises comme inhibiteurs de serine protease
TW427974B (en) Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
MX9703577A (es) Compuestos de azetidinona sustituida con azufre, utiles como agentes hipocolesterolemicos.
NO904022L (no) Fremgangsmaate for fremstilling av nye n-aryl- og n-heteroarylamid- og -urinstoffderivater.
CO5011076A1 (es) Derivados de prolina - d
ATE157870T1 (de) Ophthalmische zusammensetzung enthaltend ein 1,5- benzoxathiepin-derivat zur behandlung von glaukoma
CA2102209A1 (fr) Nouveau derive de l'isoxazole et sel de ce dernier
CO4930277A1 (es) Nuevos compuestos
HUP0104308A2 (hu) Amidino- és guanidino-azetidinon-származékok, mint triptáz inhibitorok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek
ATE90664T1 (de) 3,5-dihydroxy-6,8-nonadiensaeuren und -derivate als hypocholesterolemische mittel.
ATE103585T1 (de) Polyamin-derivate als antineoplastische wirkstoffe.
HUT54362A (en) Process for producing cumarin derivatives and pharmaceutical compositions containing them
AU690471B2 (en) Use of 1,4-dihydropyridine derivatives in the prevention and therapy of atherosclerotic degradation of arterial walls
WO1995013264A1 (fr) Derive d'acide hydroxamique et preparation medicamenteuse contenant ledit derive
RU94004910A (ru) Анестезирующее и гемостатическое средство и способ его получения
CA2261271A1 (fr) Derives de dihydrodibenzo(b,e)oxazepine, et compositions medicamenteuses les comportant
GB1334693A (en) Acenaphthene derivatives
RU94032288A (ru) Новые цефалоспориновые производные, способ их получения, фармацевтическая композиция
AU6303296A (en) Process for producing beta-amino-alpha-hydroxycarboxylic acids and derivatives thereof
JPH07278086A (ja) ヒドロキサム酸誘導体およびそれを含有する医薬製剤
ES8504712A1 (es) Un procedimiento para preparar nuevas dihidropiridinas
JPH0892191A (ja) ヒドロキサム酸誘導体およびそれを含有する医薬製剤
JPH08291127A (ja) ヒドロキサム酸誘導体およびそれを含有する医薬製剤